UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
1.
Full Text
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
The Lancet infectious diseases, ISSN 1473-3099, 2010, Volume 10, Issue 9, pp. 621 - 629
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Biological and medical sciences | Infectious diseases | Medical sciences | Bacterial diseases | Human bacterial diseases | Tuberculosis and atypical mycobacterial infections | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents | Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2016, Volume 17, Issue 1, pp. 39 - 49
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Drug Administration Schedule | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Ethylenediamines - therapeutic use | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - diagnosis | Adamantane - therapeutic use | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Adamantane - analogs & derivatives | Antitubercular Agents - therapeutic use | Medical colleges | Tuberculosis | Pharmacy | Communicable diseases | Lung diseases | Clinical trials | Drugstores | Dosage and administration | Research institutes | Rifampin | Public health | Moxifloxacin | Analysis | Studies | Consortia | Drug dosages | Index Medicus
Journal Article
Bioinformatics, ISSN 1367-4803, 05/2018, Volume 34, Issue 10, pp. 1666 - 1671
Statistics & Probability | Biochemistry & Molecular Biology | Physical Sciences | Computer Science, Interdisciplinary Applications | Life Sciences & Biomedicine | Technology | Biochemical Research Methods | Computer Science | Mathematics | Biotechnology & Applied Microbiology | Science & Technology | Mathematical & Computational Biology | Mycobacterium tuberculosis - classification | Ciprofloxacin - therapeutic use | Humans | Ofloxacin - therapeutic use | Tuberculosis, Multidrug-Resistant - genetics | Machine Learning | Pyrazinamide - therapeutic use | Microbial Sensitivity Tests | Moxifloxacin - therapeutic use | Streptomycin - therapeutic use | Isoniazid - therapeutic use | Rifampin - therapeutic use | Ethambutol - therapeutic use | Sequence Analysis, DNA - methods | Antitubercular Agents - therapeutic use | Mycobacterium tuberculosis - genetics | Tuberculosis, Multidrug-Resistant - drug therapy | Index Medicus | Original Papers
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 1/2013, Volume 207, Issue 1, pp. 9 - 17
Epidemics | Ferries | BACTERIA | Tuberculosis | Disease transmission | Mycobacterium tuberculosis | HIV | Hospital admissions | Data transmission | Multidrug resistant tuberculosis | Infection control | Genotyping | Drug resistance | Transmission | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Infectious diseases | Medical sciences | Prevalence | Humans | Male | Cross Infection - complications | Cross Infection - transmission | Adult | Extensively Drug-Resistant Tuberculosis - microbiology | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Cross Infection - epidemiology | Extensively Drug-Resistant Tuberculosis - complications | Mycobacterium tuberculosis - classification | HIV Infections - virology | South Africa - epidemiology | Genotype | Sequence Analysis, DNA | Mycobacterium tuberculosis - isolation & purification | Pyrazinamide - therapeutic use | Extensively Drug-Resistant Tuberculosis - epidemiology | Hospitals, Rural | Polymorphism, Restriction Fragment Length | Extensively Drug-Resistant Tuberculosis - transmission | Cross Infection - microbiology | HIV Infections - complications | Mutation | Cluster Analysis | Mycobacterium tuberculosis - genetics | Extensively drug-resistant tuberculosis | Distribution | Reports | Cross infection | Research | Nosocomial infections | Risk factors | Index Medicus | Abridged Index Medicus | Major and Brief Reports | transmission | drug resistance | tuberculosis | genotyping
Journal Article
The international journal of tuberculosis and lung disease, ISSN 1027-3719, 05/2015, Volume 19, Issue 5, pp. 517 - 524
Cameroon | Short-course | Treatment | Tuberculosis | Multidrug resistance | Respiratory System | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Medication Adherence - statistics & numerical data | Antitubercular Agents - adverse effects | Confidence Intervals | Prospective Studies | Humans | Middle Aged | Male | Tuberculosis, Multidrug-Resistant - diagnosis | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Isoniazid - therapeutic use | Drug Therapy, Combination | Ethambutol - therapeutic use | Odds Ratio | Antitubercular Agents - therapeutic use | Clofazimine - therapeutic use | Drug Administration Schedule | Risk Assessment | Fluoroquinolones - therapeutic use | Treatment Outcome | Kanamycin - therapeutic use | Prothionamide - therapeutic use | Pyrazinamide - therapeutic use | Drug-Related Side Effects and Adverse Reactions - epidemiology | Adolescent | Aged | Developing Countries | Cohort Studies | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9979, pp. 1738 - 1747
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Sputum - microbiology | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Treatment Outcome | Tuberculosis, Pulmonary - drug therapy | Colony Count, Microbial | Moxifloxacin | Pyrazinamide - therapeutic use | Young Adult | Nitroimidazoles - therapeutic use | Adolescent | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Clinical trials | Tuberculosis | International cooperation | Drug therapy | Pyrazinamide | Analysis | Pulmonary tuberculosis | Drug resistance | Efficiency | Index Medicus | Abridged Index Medicus
Journal Article
The international journal of tuberculosis and lung disease, ISSN 1027-3719, 02/2008, Volume 12, Issue 2, pp. 128 - 138
FQs | Modelling | Randomised clinical trial | Pulmonary tuberculosis | Respiratory System | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Sputum - microbiology | Aza Compounds - therapeutic use | Humans | Middle Aged | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Male | Colony Count, Microbial | Pyrazinamide - therapeutic use | Anti-Bacterial Agents - therapeutic use | Adolescent | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Aged | Quinolines - therapeutic use | Drug Therapy, Combination | Nonlinear Dynamics | Antitubercular Agents - therapeutic use
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2013, Volume 57, Issue 2, pp. 1019 - 1024
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Immunopathology | Tuberculosis and atypical mycobacterial infections | Viral diseases | Biological and medical sciences | Medical sciences | Immunodeficiencies | Infectious diseases | Bacterial diseases | Human bacterial diseases | Pharmacology. Drug treatments | Viral diseases of the lymphoid tissue and the blood. Aids | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Oxidoreductases, N-Demethylating - genetics | Reverse Transcriptase Inhibitors - blood | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Tuberculosis - complications | Male | Tenofovir | Young Adult | Drug Interactions | Adenine - therapeutic use | Tuberculosis - drug therapy | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Benzoxazines - blood | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Anti-HIV Agents - blood | Reverse Transcriptase Inhibitors - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | HIV Infections - blood | Pharmacogenetics | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Genotype | Pyrazinamide - therapeutic use | Benzoxazines - therapeutic use | Adolescent | HIV Infections - complications | HIV Infections - drug therapy | Polymorphism, Single Nucleotide | Cytochrome P-450 CYP2B6 | Index Medicus | Body weight | Clinical Therapeutics
Journal Article
The international journal of tuberculosis and lung disease, ISSN 1027-3719, 12/2016, Volume 20, Issue 12, pp. S38 - S41
Oxazolidinone | Tuberculosis | Bedaquiline | Clinical trial | Pretomanid | Moxifloxacin | Pyrazinamide | Extensively Drug-Resistant Tuberculosis - drug therapy | Linezolid - therapeutic use | Humans | Clinical Protocols | Fluoroquinolones - therapeutic use | Pyrazinamide - therapeutic use | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Nitroimidazoles - therapeutic use | Diarylquinolines - therapeutic use | Isoniazid - therapeutic use | Rifampin - therapeutic use | Ethambutol - therapeutic use | Research Design | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 01/2015, Volume 59, Issue 1, pp. 129 - 135
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Clofazimine - therapeutic use | Fluoroquinolones - therapeutic use | Moxifloxacin | Random Allocation | Mycobacterium tuberculosis - drug effects | Pyrazinamide - therapeutic use | Microbial Sensitivity Tests | Animals | Nitroimidazoles - therapeutic use | Diarylquinolines - therapeutic use | Oxazines - therapeutic use | Tuberculosis - drug therapy | Female | Mice | Mice, Inbred BALB C | Drug Therapy, Combination | Oxazoles - therapeutic use | Antitubercular Agents - therapeutic use | Disease Models, Animal | Index Medicus | Experimental Therapeutics
Journal Article